<DOC>
	<DOCNO>NCT02172521</DOCNO>
	<brief_summary>- Primary objective observational study gain insight effect therapy Spiriva® ( tiotropium bromide ) 18 microgram health-related quality life physical functioning patient chronic obstructive pulmonary disease ( COPD ) demonstrate hyperinflation . - Secondary objective obtain safety data regard adverse event .</brief_summary>
	<brief_title>Effect Spiriva® 18 Microgram Health-related Quality Life Physical Functioning Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Proven Hyperinflation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Women men diagnosis chronic obstructive pulmonary disease ( COPD ) thoracic gas volume ( TGV ) &gt; = 120 % measure body plethysmography Only patient yet treat Spiriva® 18 microgram include study . Patients present general specific contraindication mention Patient Information Prescribing Information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>